Empagliflozin D4

Empagliflozin D4 is a deuterated form of empagliflozin, a medication used for the treatment of type 2 diabetes. Empagliflozin D4 is a selective sodium-glucose co-transporter 2 (SGLT2) inhibitor that works by blocking the reabsorption of glucose in the kidneys, leading to increased glucose excretion in urine and lowering blood glucose levels. Empagliflozin D4 is typically administered orally in tablet form, with a recommended starting dose of 10 mg once daily. The dosage may be increased to 25 mg once daily depending on individual patient needs and response to treatment. In terms of chemical information, empagliflozin D4 has a molecular formula of C23H20D4ClO7 and a molecular weight of 460.96 g/mol. It is a white to yellowish powder that is soluble in water and ethanol. Empagliflozin D4 undergoes hepatic metabolism and is primarily eliminated through renal excretion. It has a half-life of approximately 12.4 hours, with steady-state plasma concentrations achieved after about 7 days of once-daily dosing. While empagliflozin D4 is generally well-tolerated, common side effects may include urinary tract infections, genital mycotic infections, and hypoglycemia when used in combination with insulin or sulfonylureas. It is important to consult with a healthcare provider before starting empagliflozin D4 or any other medication for diabetes management.